Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9UKU9
UPID:
ANGL2_HUMAN
Alternative names:
Angiopoietin-like protein 2
Alternative UPACC:
Q9UKU9; Q5JT58; Q8NCH7
Background:
Angiopoietin-related protein 2, also known as Angiopoietin-like protein 2, plays a crucial role in vascular development and angiogenesis. It induces sprouting in endothelial cells through both autocrine and paracrine mechanisms, highlighting its significance in the regulation of blood vessel formation.
Therapeutic significance:
Understanding the role of Angiopoietin-related protein 2 could open doors to potential therapeutic strategies. Its involvement in angiogenesis suggests its potential as a target in diseases characterized by abnormal blood vessel growth.